{"id":1020,"date":"2014-01-17T13:03:22","date_gmt":"2014-01-17T18:03:22","guid":{"rendered":"http:\/\/blinkassociates.com\/blog\/?p=1020"},"modified":"2014-01-18T14:39:03","modified_gmt":"2014-01-18T19:39:03","slug":"fdas-draft-guidance-on-interactive-promotional-media-first-week-responses","status":"publish","type":"post","link":"https:\/\/blinkassociates.com\/blog\/fdas-draft-guidance-on-interactive-promotional-media-first-week-responses\/","title":{"rendered":"FDA\u2019s Draft Guidance on Interactive Promotional Media – First Week Responses"},"content":{"rendered":"

Early Monday morning, the FDA released guidance for review on Interactive Promotional Media<\/em>. This was the first tangible guidance since the FDA hearings on Pharma Social Media in November 2009<\/span>, and for some this was a real occasion to open the champagne. Bill Evans<\/a> at the industry leading Dose of Digital<\/a> was the first to break the news. Industry pundits such as John Mack<\/a> were quick to jump on the news and agencies worked late into the night to construct elaborate points-of-view. I’ve curated a list on Scoop.it that follows the most significant commentary from this week. The links on the below embed are live, or you can click here to access the Scoop.it topic<\/a>.
\n